Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation

UTSePress Research/Manakin Repository

Search UTSePress Research

Advanced Search


My Account

Show simple item record

dc.contributor.author Valiya, S N en_US
dc.contributor.author Bajorek, Beata en_US
dc.contributor.editor en_US
dc.date.accessioned 2012-02-02T11:01:28Z
dc.date.available 2012-02-02T11:01:28Z
dc.date.issued 2005 en_US
dc.identifier 2010004375 en_US
dc.identifier.citation Valiya S N and Bajorek Beata 2005, 'Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation', Society of Hospital Pharmacists of Australia, vol. 35, no. 4, pp. 279-283. en_US
dc.identifier.issn 1445-937X en_US
dc.identifier.other C1UNSUBMIT en_US
dc.identifier.uri http://hdl.handle.net/10453/15648
dc.description.abstract Background: The benefit of warfarin for stroke prevention in non-valvular atrial fibrillation has been demonstrated in various clinical trials. Warfarin has a nan'ow therapeutic window and carries a significant risk ofbleeding. Ximelagatran is a new oral antithrombotic with predictable plasma concentrations and excellent bioavailability. Aim: To compare the costs and benefits of ximelagatran to that of warfarin and aspirin. Method: In a preliminary cost-effectiveness analysis, the costs and clinical consequences ofwarf31in, aspirin and ximelagatran were compared. The principal outcome was measured in the fonn of an incremental cost-effectiveness ratio. A decision analysis model was constructed to map the expected outcomes of three treatment alternatives. Sensitivity analysis tested the robustness of the data. en_US
dc.language en_US
dc.publisher Society of Hospital Pharmacists of Australia en_US
dc.title Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation en_US
dc.parent Journal of Pharmacy Practice and Research en_US
dc.journal.volume 35 en_US
dc.journal.number 4 en_US
dc.publocation Australia en_US
dc.identifier.startpage 279 en_US
dc.identifier.endpage 283 en_US
dc.cauo.name GSH.Pharmacy en_US
dc.conference Verified OK en_US
dc.for 111500 en_US
dc.personcode 0000069611 en_US
dc.personcode 112624 en_US
dc.percentage 100 en_US
dc.classification.name Pharmacology and Pharmaceutical Sciences en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity en_US
dc.description.keywords NA en_US
dc.staffid 112624 en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record